Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (652)

« Back to Publications

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors

Melero I. et al, (2026), Journal of Hematology & Oncology

Engineering and Improving Anti–CTLA-4 Checkpoint Inhibitors

Galvez-Cancino F. et al, (2026), Clinical Cancer Research, OF1 - OF3

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors

Rohrberg KS. et al, (2026), Journal for ImmunoTherapy of Cancer, 14, e012729 - e012729

Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations

Gomis G. et al, (2026), Trends in Immunology

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

Melero I. et al, (2026), Nature Cancer, 7, 840 - 856

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial

Melero I. et al, (2026), Nature Medicine

A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.

Garralda E. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis

Beernaert B. et al, (2026), Science Advances, 12

Intratumoral heterogeneity and immunotherapy resistance: clinical implications

Keenan BP. et al, (2026), Annals of Oncology, 37, 314 - 328

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Sanmamed MF. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 1036 - 1045

Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883

Grant M. et al, (2026), Cancers, 18, 760 - 760

Tumor-targeted 4-1BB costimulation enhances immune activation and clinical activity of a CEA-directed T-cell engager in microsatellite-stable colorectal cancer

Boehnke A. et al, (2026)

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026), Clinical Cancer Research, 32, 528 - 539

Supplementary Figure 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Figure 5 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Load More

1
2
3
4
5
6
7
...
»